Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
3.45
Dollar change
-0.02
Percentage change
-0.58
%
IndexRUT P/E- EPS (ttm)-0.29 Insider Own36.11% Shs Outstand68.28M Perf Week-6.76%
Market Cap237.91M Forward P/E- EPS next Y-0.42 Insider Trans-0.00% Shs Float44.06M Perf Month17.75%
Income-29.07M PEG- EPS next Q-0.09 Inst Own43.59% Short Float2.43% Perf Quarter139.58%
Sales0.00M P/S- EPS this Y-40.80% Inst Trans43.28% Short Ratio3.86 Perf Half Y54.02%
Book/sh1.21 P/B2.85 EPS next Y-2.86% ROA-27.37% Short Interest1.07M Perf Year91.67%
Cash/sh1.20 P/C2.87 EPS next 5Y- ROE-30.59% 52W Range0.97 - 4.00 Perf YTD157.46%
Dividend Est.- P/FCF- EPS past 5Y27.24% ROI-34.78% 52W High-13.75% Beta0.87
Dividend TTM- Quick Ratio15.03 Sales past 5Y0.00% Gross Margin- 52W Low255.67% ATR (14)0.28
Dividend Ex-Date- Current Ratio15.03 EPS Y/Y TTM46.58% Oper. Margin0.00% RSI (14)65.63 Volatility6.11% 9.27%
Employees25 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.33
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-40.11% Payout- Rel Volume0.42 Prev Close3.47
Sales Surprise- EPS Surprise12.76% Sales Q/Q- EarningsMar 20 AMC Avg Volume277.57K Price3.45
SMA208.49% SMA5044.88% SMA20070.21% Trades Volume117,188 Change-0.58%
Date Action Analyst Rating Change Price Target Change
Apr-12-23Initiated B. Riley Securities Buy $6
Nov-22-22Initiated SVB Leerink Outperform $6
Jun-03-19Initiated SVB Leerink Outperform $14
Jun-03-19Initiated Stifel Buy $20
Jun-03-19Initiated Needham Buy $18
Jun-03-19Initiated BMO Capital Markets Outperform $15
Mar-21-24 10:46AM
Mar-20-24 08:53PM
05:33PM
04:05PM
Mar-13-24 04:05PM
07:30AM Loading…
Feb-28-24 07:30AM
Feb-06-24 07:30AM
Jan-17-24 12:00PM
Jan-04-24 07:30AM
Dec-05-23 07:30AM
Nov-30-23 09:35AM
Nov-14-23 09:55AM
09:35AM
Nov-12-23 11:13AM
Nov-09-23 04:05PM
07:30AM Loading…
Nov-02-23 07:30AM
Nov-01-23 04:05PM
Oct-13-23 08:30AM
Oct-11-23 12:00PM
Sep-06-23 07:30AM
Aug-12-23 08:30AM
Aug-11-23 06:44AM
Aug-10-23 04:05PM
Aug-03-23 04:05PM
Aug-01-23 07:30AM
Jul-06-23 07:30AM
Jun-04-23 10:45AM
May-30-23 07:30AM
May-22-23 04:05PM
May-16-23 11:46AM
06:38AM Loading…
May-12-23 06:38AM
May-11-23 04:05PM
May-10-23 08:48AM
May-09-23 07:30AM
May-04-23 04:05PM
May-02-23 07:30AM
Apr-27-23 07:30AM
Apr-11-23 04:05PM
Mar-18-23 02:03AM
Mar-17-23 06:19AM
Mar-16-23 04:05PM
Mar-09-23 04:05PM
Mar-08-23 07:30AM
Mar-06-23 04:05PM
Feb-21-23 07:00AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-25-23 09:00AM
Jan-05-23 04:05PM
Dec-26-22 08:26AM
Dec-19-22 04:05PM
Nov-14-22 04:05PM
Nov-10-22 04:05PM
Nov-08-22 07:30AM
Nov-03-22 04:05PM
Oct-27-22 07:30AM
Sep-30-22 09:40AM
Sep-23-22 01:18AM
Sep-22-22 04:01PM
Sep-19-22 09:35AM
07:30AM
Sep-14-22 09:40AM
Sep-07-22 07:30AM
Aug-30-22 04:05PM
Aug-24-22 07:30AM
Aug-22-22 09:30AM
Aug-11-22 04:05PM
Aug-09-22 07:30AM
Aug-04-22 05:41PM
Jul-21-22 06:45AM
Jul-19-22 09:13AM
Jul-14-22 09:00AM
Jul-07-22 07:30AM
Jun-30-22 12:53PM
Jun-29-22 08:37AM
08:36AM
07:30AM
Jun-23-22 10:58AM
Jun-07-22 07:30AM
May-12-22 04:05PM
May-05-22 04:05PM
May-03-22 07:30AM
Apr-13-22 04:25PM
Apr-11-22 08:00AM
Apr-07-22 08:00AM
Apr-05-22 04:25PM
Mar-23-22 03:25PM
Mar-22-22 07:30AM
Mar-17-22 04:05PM
Mar-15-22 07:30AM
Mar-09-22 04:05PM
Feb-24-22 07:55AM
07:30AM
Feb-01-22 07:30AM
Jan-25-22 10:00AM
Jan-05-22 07:00AM
Dec-16-21 04:05PM
Dec-01-21 08:22AM
Nov-18-21 10:21AM
Nov-15-21 07:30AM
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Delfini LisaChief Financial OfficerOct 11 '23Option Exercise0.512,2921,17136,686Oct 12 04:00 PM
Delfini LisaChief Financial OfficerOct 11 '23Sale2.027851,58635,901Oct 12 04:00 PM
Delfini LisaChief Financial OfficerSep 11 '23Option Exercise0.512,2911,17135,105Sep 13 04:06 PM
Delfini LisaChief Financial OfficerSep 11 '23Sale2.207111,56434,394Sep 13 04:06 PM
Delfini LisaChief Financial OfficerAug 11 '23Option Exercise0.512,2921,17133,496Aug 14 04:00 PM
Delfini LisaChief Financial OfficerAug 11 '23Sale2.366821,61032,814Aug 14 04:00 PM
Delfini LisaChief Financial OfficerJul 11 '23Option Exercise0.512,2921,17131,891Jul 12 04:29 PM
Delfini LisaChief Financial OfficerJul 11 '23Sale2.346871,60831,204Jul 12 04:29 PM
Simon FarrellChief Commercial OfficerJun 20 '23Option Exercise0.516,2503,19445,650Jun 21 04:00 PM
Delfini LisaChief Financial OfficerJun 12 '23Option Exercise0.512,2911,17130,209Jun 14 04:28 PM
Delfini LisaChief Financial OfficerJun 12 '23Sale2.646101,61029,599Jun 14 04:28 PM
Delfini LisaChief Financial OfficerMay 11 '23Option Exercise0.512,2911,17128,480May 15 04:00 PM
Delfini LisaChief Financial OfficerMay 11 '23Sale2.895621,62427,918May 15 04:00 PM
Delfini LisaChief Financial OfficerApr 11 '23Option Exercise0.512,2921,17127,029Apr 12 05:02 PM
Delfini LisaChief Financial OfficerApr 11 '23Sale1.848401,54526,189Apr 12 05:02 PM